Cipla Ltd · NSE:CIPLA
Cipla — Q1 FY21 Earnings Presentation
15 slides from Cipla's earnings presentation, Aug 7, 2020
Slide 1: Exchange filing cover letter: Investor Presentation
7th August, 2020 [Grab your reader’s attention with a great quote from the document or use this space to emphasize a key point. To place (1) BSE Limited (2) National Stock Exchange of India Limited this text box anywhere on the page, just drag it.] Listing Department, Listing Department [Cite your s
Slide 2: Investor Presentation Q1FY21
Investor Presentation Q1FY21 07-08-2020
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward- looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors tha
Slide 4: Cipla's efforts in combatting Covid-19
Cipla’s efforts in combatting Covid-19 Delivering on our promise of ‘Caring for life’ Patients Physicians Employees ▪ Supported onboarding of 10K+ ▪ Comprehensive presence across doctors on multiple telehealth ▪ Embracing changed working the Covid care continuum platforms to facilitate on-demand nor
Slide 5: Strong Start to FY21!
Strong Start to FY21! Business re-imagination, resilient operations and lower costs drive Q1 performance 1 Strong EBITDA margin expansion led by cost control Overall 9% Revenues (YoY Growth) 24% ~145bps YoY expansion 16% ~923bps QoQ expansion 61% QoQ Q1FY21 YoY Strong growth across branded franchise
Slide 6: Significant efforts and focus across the organization to enable business operations
Significant efforts and focus across the organization to enable business operations 1 Business Re-imagination 2 Significantly lower costs Accelerated digital adoption to Strong optimization by identifying connect healthcare ecosystem avenues for reduction of cost and identifying value generating dri
Slide 7: Financial Performance – Q1FY21
Financial Performance – Q1FY21 Revenues INR 4,346 Cr 9% EBITDA INR 1,049 Cr │ 24% 16% YoY Q1 FY21 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs Q1 FY 20 (Rs Cr) 4% 2% Total Revenue from Europe, 6% 4,346 9% Operations Emerging India, 37% EBITDA 1,049 16% Mkts, 11% EBITDA % of revenu
Slide 8: India (Rx + Gx + CHL): Resilient execution driving growth across businesses in India
India (Rx + Gx+ CHL1) : Resilient execution driving growth across businesses in India Key Business Highlights2 Q1 Y-o-Y Rs Cr ▪ The Rx business grew 9% YoY led by strong traction in chronic therapies despite lock down challenges; continued servicing of 1,608 patients with Covid portfolio 16% 1,388 ▪
Slide 9: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access Q1 Y-o-Y $ Mn South Africa Market 23 17% Q1 YoY 28 ZAR Terms 30 25 South Africa Private South Africa Tender South Africa Private 24% Q1 YoY 6% Q1 YoY South Africa 48 47 ZAR Terms ZAR Terms Tender Others (SSA & CGA) Q1 FY20 Q1 FY21 Key B
Slide 10: North America: Significant growth driven by new launches and Albuterol ramp-up
North America: Significant growth driven by contribution from new launches and Albuterol ramp-up Continued momentum DHE Nasal spray Generic Albuterol Launch of Icatibant in complex and launched with 180 ramp-up on track pre-filled syringe differentiated launches day CGT exclusivity Key Business High
Slide 11: ANDA Portfolio & Pipeline (As on 30th June 2020)
ANDA1 Portfolio & Pipeline (As on 30th June 2020) Total 175 21 66 262 ANDAs 200 ANDA Portfolio 180 160 29 140 120 57 100 80 9 60 4 21 40 80 3 20 1 3 38 11 0 6 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs 1 Does not include Vet product ANDA
Slide 12: Emerging Markets, Europe and API
Emerging Markets, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn 60 32 29 9% 26 -7% 24 50% 40 Q1 FY20 Q1 FY21 Q1 FY20 Q1 FY21 Q1 FY20 Q1 FY21 ▪ Growth in the quarter driven by strong demand and base effect from last ▪ Strong performance in key DTM1 ▪ Adjusted YoY revenue growth at 11% yea
Slide 13: Continued progress across our key strategic priorities
Continued progress across our key strategic priorities South Africa1 & Lung leadership One-India US Generics Emerging markets across markets • Continue to drive synergies • Private market execution in • Continue to build the US • Leveraging Cipla’s drug- across the three businesses SA Generics pipel
Slide 14: Priorities for the coming quarters: Sustaining growth through the pandemic
Priorities for the coming quarters: Sustaining growth through the pandemic Sustaining leadership in the post pandemic environment o Business re-imagination and cost optimisation for adapting to the new normal and continued 1 delivery across multiple strategic priorities o Proactively de-risking the
Slide 15: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q1FY21 14